Literature DB >> 2541537

The surface gene promoter of the human hepatitis B virus displays a preference for differentiated hepatocytes.

H K Chang1, L P Ting.   

Abstract

By transfections of hepatitis B virus (HBV) DNA into five human hepatoma cell lines with the characteristics of differentiated human hepatocytes, three human hepatoma cell lines possessing partial hepatocyte-associated markers, and one non-liver cell line, we demonstrated that the expression of hepatitis B surface and core genes preferentially occurred in hepatoma cell lines with differentiated hepatocyte-associated characteristics. With a heterologous CAT gene as a reporter, the transcriptional activity of the promoter region containing both the distal (SPI) and the proximal (SPII) promoters of hepatitis B surface gene was found to show a preference for differentiated hepatoma cell lines. The SPI promoter which produces a RNA transcript for the synthesis of the large surface protein shows a strong preference, at least 750-fold, for differentiated hepatoma cells, while the SPII promoter which produces RNA transcripts for the synthesis of the middle and major surface proteins shows a moderate preference, about 20- to 59-fold. Further study indicates that this 750-fold preference of the SPI transcriptional activity for differentiated hepatoma cell lines can be attributed to the regulatory sequences of both the SPI and the HBV enhancer regions. These results also imply the important role of the large surface protein of HBV on the hepatocyte-specific infectivity of this virus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541537     DOI: 10.1016/0042-6822(89)90364-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Transcriptional repression of human hepatitis B virus genes by a bZIP family member, E4BP4.

Authors:  C K Lai; L P Ting
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  C/EBP-like proteins binding to the functional box-alpha and box-beta of the second enhancer of hepatitis B virus.

Authors:  C H Yuh; L P Ting
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

3.  The ubiquitous transcription factor Oct-1 and the liver-specific factor HNF-1 are both required to activate transcription of a hepatitis B virus promoter.

Authors:  D X Zhou; T S Yen
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

4.  A liver-specific nuclear factor interacts with the promoter region of the large surface protein gene of human hepatitis B virus.

Authors:  H K Chang; B Y Wang; C H Yuh; C L Wei; L P Ting
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

5.  Hepatocyte-like cells transdifferentiated from a pancreatic origin can support replication of hepatitis B virus.

Authors:  Robert Yung-Liang Wang; Chia-Ning Shen; Min-Hui Lin; David Tosh; Chiaho Shih
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  The genome of hepatitis B virus contains a second enhancer: cooperation of two elements within this enhancer is required for its function.

Authors:  C H Yuh; L P Ting
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

7.  Hepatitis B virus differentially suppresses myelopoiesis and displays tropism for immature hematopoietic cells.

Authors:  G K Sing; S Prior; A Fernan; G Cooksley
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  Transcriptional and posttranscriptional control of hepatitis B virus gene expression.

Authors:  Susan L Uprichard; Stefan F Wieland; Alana Althage; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

Review 9.  Hepatitis B virus infection and primary hepatocellular carcinoma.

Authors:  M Feitelson
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

10.  Differentiated liver cell specificity of the second enhancer of hepatitis B virus.

Authors:  C H Yuh; L P Ting
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.